Public comment period · §3
Draft monograph: Mazdutide — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-MAZDUTIDE-MO/002 | Dr Yaa Kettlewell | Anti-drug antibody data are omitted | Accepted in part |
| DRAFT-MAZDUTIDE-MO/003 | Dr Séverin Oppenheimer-Ade | Quantitative claims are reproduced without the method that produced them | Accepted |
| DRAFT-MAZDUTIDE-MO/007 | Dr Vittoria Ylönen | Regulatory status is stated without naming the jurisdiction | Accepted |
| DRAFT-MAZDUTIDE-MO/001 | Vasilisa Sandringham-Adu | The compound is supplied under names the monograph does not list | Accepted |
| DRAFT-MAZDUTIDE-MO/006 | Dr Anselm Thorsby-Nakamura | The indication table mixes approved indications with uses for which the compound is merely supplied | Accepted |
| DRAFT-MAZDUTIDE-MO/009 | Dr Abimbola Sotomayor-Ekwueme | A purity figure from a certificate is quoted as though it were a content figure | Accepted |
| DRAFT-MAZDUTIDE-MO/008 | Dr Mordecai Glendinning-Uche | Every contributing trial shares one sponsor and the monograph does not say so | Accepted |
| DRAFT-MAZDUTIDE-MO/004 | Dr Lorcan Trelawney | The document should state what a reader ought to do | Not accepted |
| DRAFT-MAZDUTIDE-MO/005 | Dr Torvald Kettlewell | The same concept is given three different names in one document | Accepted |
| 9 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 7 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 1 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 0 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 1 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- Anti-drug antibody data are omitted — arising from DRAFT-MAZDUTIDE-MO/002. Anti-drug antibody incidence and any reported association with loss of effect are now reported where measured, and recorded as not measured where the contributing trials did not assess them.
- Quantitative claims are reproduced without the method that produced them — arising from DRAFT-MAZDUTIDE-MO/003. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
- Regulatory status is stated without naming the jurisdiction — arising from DRAFT-MAZDUTIDE-MO/007. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
- The compound is supplied under names the monograph does not list — arising from DRAFT-MAZDUTIDE-MO/001. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
- The indication table mixes approved indications with uses for which the compound is merely supplied — arising from DRAFT-MAZDUTIDE-MO/006. The indication table now carries a status column with three values, approved, under investigation and supplied without trial evidence, and the value is stated for every row. Rows in the third category also state that no certainty rating is assigned because…
- A purity figure from a certificate is quoted as though it were a content figure — arising from DRAFT-MAZDUTIDE-MO/009. Purity and content are now reported in separate rows with separate definitions, and the monograph states that a purity figure sets no bound on content and that a content figure requires a determination against a standard of assigned content.
- Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-MAZDUTIDE-MO/008. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
- The same concept is given three different names in one document — arising from DRAFT-MAZDUTIDE-MO/005. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-065/3 · https://compoundevidence.com/comment-periods/draft-mazdutide-monograph/disposition/ · retrieved 30 July 2026